Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
On February 15, 2017, the European Parliament voted to
approve the Canada-EU Comprehensive Economic and Trade Agreement
(CETA). This approval paves the way for provisional
application of CETA rules in Europe as early as April 1, 2017,
although full implementation will require ratification by each EU
member state. As
previously reported, Canada is in the process of implementation
through Bill C-30, which proposes to amend several important
provisions under the Patent Act and Trademarks
Act. Bill C-30 passed third reading in the House of Commons
and was introduced to the Senate on February 14,
2017.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
